-
First patient treated with the GROSSO® implant as part of the First In Human clinical trial
Working with the Institute of Ocular Micro Surgery (IMO) in Barcelona, Spain, we achieved a very monumental milestone in the First In Human clinical trial.
-
Welcoming on board Dr. Letizia Mansutti, MD, Ophthalmic Surgeon, Angel Investor and Board Member in our company
We are pleased to have on board Dr. Letizia Mansutti, MD, Ophthalmic Surgeon, Angel Investor and Board Member in Recornea.
-
Regulatory approvals to conduct the First In Human Clinical trial and Conducting the Site Initiation Visit to kick-off the activities
We are thrilled to announce that we received regulatory approvals to conduct the First In Human Clinical Trial for our fist-line medical device for the treatment of keratoconus in Spain. Thus, Recornea is entering the clinical phase in humans.
-
Welcoming on board Dr. Rossella Baldini as Clinical Trial Manager in our company
We are very pleased to announce and welcome Dr. Rossella Baldini as a Clinical Trial Manager on board in our team at RECORNEA.
Preventing your blindness through innovation
It's not about ideas.
It's about making ideas happen.
Innovative Eye Care Solutions
Recornea technologies prevent blindness through proprietary technology that creates innovative minimally-invasive products for ophthalmic applications. The technology couples minimally invasive surgery with biocompatible and bio-enhanced devices to treat diseases of the eye.
Our technology:
- Nitinol A super elastic, shape-memory alloy.
- Biocompatible devices designed for natural integration/engineered for safety.
- Minimally invasive procedures Faster healing, less pain.
Pioneering the Future of Ophthalmology
RECORNEA pioneers advanced medical solutions for diseases of the eye. Our flagship GROSSO® Reshaper is the world's first-ever nitinol intracorneal implant designed to treat keratoconus, a condition that causes progressive thinning and bulging of the cornea resulting in poor quality of vision. By leveraging the unique properties of shape-memory and super-elastic materials, we are developing a pipeline of innovative minimally-invasive devices to address a wide range of ocular conditions, including glaucoma and keratoconus.
Supported by Fundings & Patents
Recornea raised around €2.4 M in non-dilutive and €0.9 M in dilutive funding for the core platform proprietary technology. Recornea will spin out multiple innovative products such as for glaucoma related ailments and others in the coming years.
Updates from Recornea world